nach oben

AIDS and Behavior

Erschienen in:

01.08.2010 | Original Paper

Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis

verfasst von: Monica Malta, Monica M. F. Magnanini, Steffanie A. Strathdee, Francisco I. Bastos

Erschienen in: AIDS and Behavior | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

We conducted a meta-analysis of studies assessing adherence to highly active antiretroviral therapy (HAART) and a qualitative systematic review of factors associated with better HAART outcomes among HIV+ drug users (DU). Thirty-eight studies were considered, which analyzed 14,960 patients (11,394 HIV+ DU, 76.2%). Overall adherence (pooled percent of DU classified as adherent in each study) was 0.60 (95% CI: 0.52–0.68), similar to levels identified by studies conducted with HIV+ patients who are not drug users. Time frame used to measure adherence was an independent predictor of inter-study heterogeneity. The systematic review identified better HAART outcomes among former DU, those with less severe psychiatric conditions, those receiving opioid substitution therapy and/or psychosocial support. Patients initiating HAART with lower viral load and higher CD4 counts, and those without co-infections also had better treatment outcomes. Our findings suggest that HIV+ DU tend to be inappropriately assumed to be less adherent and unlikely to achieve desirable treatment outcomes, when compared to their non-DU cohort.

Aceijas, C., Oppenheimer, E., Stimson, G. V., Ashcroft, R. E., Matic, S., & Hickman, M. (2006). Antiretroviral treatment for injecting DU in developing and transitional countries 1 year before the end of the “Treating 3 million by 2005. Making it happen. The WHO strategy” (“3 by 5”). Addiction (Abingdon, England), 101, 1246–1253. doi:10.1111/j.1360-0443.2006.01509.x.

Altice, F. L., Mezger, J. A., Hodges, J., Bruce, R. D., Marinovich, A., Walton, M., et al. (2004). Developing a directly administered antiretroviral therapy intervention for HIV-infected DU: Implications for program replication. Clinical Infectious Diseases, 38, S376–S387. doi:10.1086/421400.CrossRefPubMed

Altice, F. L., Mostashari, F., & Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28, 47–58.PubMed

Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., et al. (2001). The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Annals of Internal Medicine, 134, 663–694.PubMed

Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected DU: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33, 1417–1423. doi:10.1086/323201.CrossRefPubMed

Arnsten, J. H., Li, X., Mizuno, Y., Knowlton, A. R., Gourevitch, M. N., Handley, K., et al. (2007). Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. Journal of Acquired Immune Deficiency Syndromes, 46, S64–S71.CrossRefPubMed

Atkinson, J. S., Schönnesson, L. N., Williams, M. L., & Timpson, S. C. (2008). Associations among correlates of schedule adherence to antiretroviral therapy (ART): A path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection. AIDS Care, 20, 253–262. doi:10.1080/09540120701506788.CrossRefPubMed

Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. The American Journal on Addictions, 10, 69–78. doi:10.1080/105504901750160501.CrossRefPubMed

Bangsberg, D. R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939–941. doi:10.1086/507526.CrossRefPubMed

Bassetti, S., Battegay, M., Furrer, H., Rickenbach, M., Flepp, M., Kaiser, L., et al. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort study. Journal of Acquired Immune Deficiency Syndromes, 21, 114–119.PubMed

Berlin, J. A. (1995). Invited commentary. American Journal of Epidemiology, 142, 383–387.PubMed

Bouhnik, A. D., Chesney, M., Carrieri, P., Gallais, H., Moreau, J., Moatti, J. P., et al. (2002). Nonadherence among HIV-infected injecting DU: The impact of social instability. Journal of Acquired Immune Deficiency Syndromes, 31, S149–S153.PubMed

Bouhnik, A. D., Preau, M., Vincent, E., Carrieri, M. P., Gallais, H., Lepeu, G., et al. (2005). Depression and clinical progression in HIV-infected DU treated with highly active antiretroviral therapy. Antiviral Therapy, 10, 53–61.PubMed

Carrieri, M. P., Chesney, M. A., Spire, B., Loundou, A., Sobel, A., Lepeu, G., et al. (2003a). Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting DU. International Journal of Behavioral Medicine, 10, 1–14. doi:10.1207/S15327558IJBM1001_01.CrossRefPubMed

Carrieri, M. P., Raffi, F., Lewden, C., Sobel, A., Michelet, C., Cailleton, V., et al. (2003b). Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antiviral Therapy, 8, 585–594.PubMed

Celentano, D. D., Galai, N., Sethi, A. K., Shah, N. G., Strathdee, S. A., Vlahov, D., et al. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection DU. AIDS (London, England), 15, 1707–1715.

Celentano, D. D., Vlahov, D., Cohn, S., Shadle, V. M., Obasanjo, O., & Moore, R. D. (1998). Self-reported antiretroviral therapy in injection DU. JAMA: The Journal of the American Medical Association, 280, 544–546. doi:10.1001/jama.280.6.544.CrossRef

Chesney, M. A. (2006). The Elusive Gold Standard: Future Perspectives for HIV Adherence Assessment and Intervention. Journal of Acquired Immune Deficiency Syndromes, 43, S149–S155. doi:10.1097/01.qai.0000243112.91293.26.CrossRefPubMed

Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, 255–266.CrossRefPubMed

Clarke, S., Delamere, S., McCullough, L., Hopkins, S., Bergin, C., & Mulcahy, F. (2003). Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting DU. HIV Medicine, 4, 33–37. doi:10.1046/j.1468-1293.2003.00130.x.CrossRefPubMed

Cofrancesco, J., Jr., Scherzer, R., Tien, P. C., Gibert, C. L., Southwell, H., Sidney, S., et al. (2008). Illicit drug use and HIV treatment outcomes in a US cohort. AIDS (London, England), 22, 357–365.

Cooper, H., & Hedges, L. V. (1994). The handbook of research synthesis. New York: Russell Sage Foundation.

Crisp, B. R., Williams, M., Timpson, S., & Ross, M. W. (2004). Medication compliance and satisfaction with treatment for HIV disease in a sample of African–American crack cocaine smokers. AIDS and Behavior, 8, 199–206. doi:10.1023/B:AIBE.0000030250.33931.af.CrossRefPubMed

Crystal, S., Sambamoorthi, U., Moynihan, P. J., & McSpiritt, E. (2001). Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. Journal of General Internal Medicine, 16, 850–859. doi:10.1046/j.1525-1497.2001.01025.x.CrossRefPubMed

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177–188. doi:10.1016/0197-2456(86)90046-2.CrossRefPubMed

Des Jarlais, D. C., Lyles, C., & Crepaz, N. (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. American Journal of Public Health, 94, 361–366.CrossRefPubMed

Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). Do HIV-infected injecting DU over-report adherence to highly active antiretroviral therapy? A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS (London, England), 15, 1075–1077. doi:10.1097/00002030-200105250-00024.

Egger, M., May, M., Chene, G., Phillips, A. N., Ledergerber, B., Dabis, F., et al. (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet, 360, 119–129. doi:10.1016/S0140-6736(02)09411-4.CrossRefPubMed

Escobar, I., Campo, M., Martin, J., Fernandez-Shaw, C., Pulido, F., & Rubio, R. (2003). Factors affecting patient adherence to highly active antiretroviral therapy. The Annals of Pharmacotherapy, 37, 775–781. doi:10.1345/aph.1C427.CrossRefPubMed

Fleiss, J. L. (1993). The statistical basis of meta-analysis. Statistical Methods in Medical Research, 2, 121–145. doi:10.1177/096228029300200202.CrossRefPubMed

Friedland, G., & Williams, A. (1999). Attaining higher goals in HIV treatment: The central importance of adherence. AIDS (London, England), 13(Suppl 1), S61–S72.

Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (London, England), 13, 1763–1769. doi:10.1097/00002030-199909100-00021.

Haug, N. A., Sorensen, J. L., Lollo, N. D., Gruber, V. A., Delucchi, K. L., & Hall, S. M. (2005). Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care, 17, 1022–1029. doi:10.1080/09540120500100882.CrossRefPubMed

Hedges, L. V., & Vevea, J. L. (1998). Fixed and random effects models in meta-analysis. Psychological Methods, 3, 486–504. doi:10.1037/1082-989X.3.4.486.CrossRef

Higgins, J. P., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539–1558. doi:10.1002/sim.1186.CrossRefPubMed

Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.), 327, 557–560. doi:10.1136/bmj.327.7414.557.CrossRef

Hinkin, C. H., Barclay, T. R., Castellon, S. A., Levine, A. J., Durvasula, R. S., Marion, S. D., et al. (2007). Drug use and medication adherence among HIV-1 infected individuals. AIDS and Behavior, 11, 185–194. doi:10.1007/s10461-006-9152-0.CrossRefPubMed

Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J., O’Shaughnessy, M. V., Schechter, M. T., et al. (1998). Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA: The Journal of the American Medical Association, 279, 450–454. doi:10.1001/jama.279.6.450.CrossRef

Howard, A. A., Arnsten, J. H., Vlahov, D., Rich, J. D., Schuman, P., Stone, V. E., et al. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (London, England), 16, 2175–2182. doi:10.1097/00002030-200211080-00010.

Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychological Methods, 11, 193–206. doi:10.1037/1082-989X.11.2.193.CrossRefPubMed

Inciardi, J. A., & Surratt, H. L. (2001). Cross-cultural approaches to harm reduction research: Some considerations on the Brazil experience. Substance Use & Misuse, 36, 201–212.CrossRef

Kerr, T., Marshall, A., Walsh, J., Palepu, A., Tyndall, M., Montaner, J., et al. (2005). Determinants of HAART discontinuation among injection drug users. AIDS Care, 17, 539–549.PubMed

Kerr, T., Palepu, A., Barness, G., Walsh, J., Hogg, R., Montaner, J., et al. (2004). Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antiviral Therapy, 9, 407–414.PubMed

Knowlton, A., Arnsten, J., Eldred, L., Wilkinson, J., Gourevitch, M., Shade, S., et al. (2006). Individual, interpersonal, and structural correlates of effective HAART use among urban active injection DU. Journal of Acquired Immune Deficiency Syndromes, 41, 486–492. doi:10.1097/01.qai.0000186392.26334.e3.CrossRefPubMed

Latkin, C. A., Knowlton, A. R., Sherman, S. (2001). Routes of drug administration, differential affiliation, and lifestyle stability among cocaine and opiate users: Implications to HIV prevention. Journal of Substance Abuse, 13, 89–102.CrossRef

Lipsey, M. W., & Wilson, D. B. (2001). Practical meta-analysis. Thousand Oaks: Sage.

Liu, H., Longshore, D., Williams, J. K., Rivkin, I., Loeb, T., Warda, U. S., et al. (2006). Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS and Behavior, 10, 279–286. doi:10.1007/s10461-005-9041-y.CrossRefPubMed

Lu, M., Safren, S. A., Skolnik, P. R., Rogers, W. H., Coady, W., Hardy, H., et al. (2008). Optimal recall period and response task for self-reported HIV medication adherence. AIDS and Behavior, 12, 86–94. doi:10.1007/s10461-007-9261-4.CrossRefPubMed

Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251–259.PubMed

Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (London, England), 16, 767–774. doi:10.1097/00002030-200203290-00012.

Malta, M., Strathdee, S. A., Magnanini, M. M. F., & Bastos, F. I. (2008). Adherence to antiretroviral therapy for HIV/AIDS among drug users—a systematic review. Addiction (Abingdon, England), 103, 1242–1257. doi:10.1111/j.1360-0443.2008.02269.x.

Martin, L. L., Hermandez, S. O., & Carrobles, J. A. (2005). Psychosocial variables in the antiretroviral treatment adherence in methadone maintenance patients [Article in Spanish]. Psicothema, 17, 575–581.

Martini, M., Recchia, E., Nasta, P., Castanotto, D., Chiaffarino, F., Parazzini, F., et al. (2004). Illicit drug use: Can it predict adherence to antiretroviral therapy? European Journal of Epidemiology, 19, 585–587. doi:10.1023/B:EJEP.0000032353.03967.ef.CrossRefPubMed

Martín-Sánchez, V., Ortega-Valín, L., Pérez-Simón Mdel, R., Mostaza-Fernández, J. L., Ortiz de Urbina-González, J. J., Rodríguez-María, M., et al. (2002). Factors predicting lack of adherence to highly active antiretroviral treatment. Enfermedades Infecciosas y Microbiología Clínica, 20, 491–497. [Article in Spanish].PubMed

Mathers, B. M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S. A., et al. (2008). Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. The Lancet, 372(9651), 1733–1745. doi:10.1016/S0140-6736(08)61311-2.

McNabb, J., Ross, J. W., Abriola, K., Turley, C., Nightingale, C. H., & Nicolau, D. P. (2001). Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases, 33, 700–705. doi:10.1086/322590.CrossRefPubMed

Miller, M. F., Haley, C., Koziel, M. J., & Rowley, C. F. (2005). Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clinical Infectious Diseases, 41, 713–720. doi:10.1086/432618.CrossRefPubMed

Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., et al. (2006). Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA : The Journal of the American Medical Association, 296, 679–690. doi:10.1001/jama.296.6.679.CrossRef

Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., & Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting DU: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS (London, England), 14, 151–155. doi:10.1097/00002030-200001280-00010.

Moher, D., Coo, D. J., Eastwood, S., Olin, I., Rennie, D., & Stroup, D. F. (2000). Improving the quality of reports of meta-analysis of randomized controlled trials: The QUOROM Statement. British Journal of Surgery, 87, 1448–1454. doi:10.1046/j.1365-2168.2000.01610.x.CrossRefPubMed

Moher, D., Schulz, K. F., & Altman, D. G. (2001). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357, 1191–1194. doi:10.1016/S0140-6736(00)04337-3.CrossRefPubMed

New York State Department of Health. (2005). Adherence to antiretroviral therapy among substance users. New York (NY): New York State Department of Health.

Palella, F. J., Jr, Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338, 853–860. doi:10.1056/NEJM199803263381301.CrossRefPubMed

Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., & Samet, J. H. (2004a). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction (Abingdon, England), 99, 361–368. doi:10.1111/j.1360-0443.2003.00670.x.

Palepu, A., Tyndall, M. W., Chan, K., Wood, E., Montaner, J. S., & Hogg, R. S. (2004b). Initiating highly active antiretroviral therapy and continuity of HIV care: The impact of incarceration and prison release on adherence and HIV treatment outcomes. Antiviral Therapy, 9, 713–719.PubMed

Palepu, A., Tyndall, M. W., Joy, R., Kerr, T., Wood, E., Press, N., et al. (2006). Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection DU: The role of methadone maintenance therapy. Drug and Alcohol Dependence, 84, 188–194. doi:10.1016/j.drugalcdep.2006.02.003.CrossRefPubMed

Palepu, A., Tyndall, M. W., Li, K., Yip, B., O’Shaughnessy, M. V., Schechter, M. T., et al. (2003a). Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection DU starting antiretroviral therapy. Journal of Urban Health, 80, 667–675. doi:10.1093/jurban/jtg073.PubMed

Palepu, A., Tyndall, M., Yip, B., O’Shaughnessy, M. V., Hogg, R. S., & Montaner, J. S. (2003b). Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes, 32, 522–526. doi:10.1097/00126334-200304150-00009.CrossRefPubMed

Parruti, G., Manzoli, L., Toro, P. M., D’Amico, G., Rotolo, S., Graziani, V., et al. (2006). Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. AIDS Patient Care and STDs, 20, 48–56.CrossRefPubMed

Pearson, C. R., Micek, M. A., Simoni, J. M., Hoff, P. D., Matediana, E., Martin, D. P., et al. (2007a). Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. Journal of Acquired Immune Deficiency Syndromes, 46, 238–244. doi:10.1097/QAI.0b013e318153f7ba.CrossRefPubMed

Pearson, C. R., Simoni, J. M., Hoff, P., Kurth, A. E., & Martin, D. P. (2007b). Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues. AIDS and Behavior, 11, 161–173. doi:10.1007/s10461-006-9133-3.CrossRefPubMed

Pinheiro, C., De-Carvalho-Leite, J., Drachler, M., & Silveira, V. L. (2002). Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in southern Brazil. Brazilian Journal of Medical and Biological Research, 35, 1173–1181.PubMed

Pradier, C., Carrieri, P., Bentz, L., Spire, B., Dellamonica, P., Moreau, J., et al. (2001). Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDU. International Journal of STD and AIDS, 12, 324–328. doi:10.1258/0956462011923165.CrossRefPubMed

Purcell, D. W., Metsch, L. R., Latka, M., Santibanez, S., Gomez, C. A., Eldred, L., et al. (2004). Interventions for seropositive injectors-research and evaluation: An integrated behavioral intervention with HIV-positive injection DU to address medical care, adherence, and risk reduction. Journal of Acquired Immune Deficiency Syndromes, 37, S110–S118. doi:10.1097/01.qai.0000140609.44016.c4.CrossRefPubMed

Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., et al. (2000). Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. The New England Journal of Medicine, 342, 921–929. doi:10.1056/NEJM200003303421303.CrossRefPubMed

R Core Development Core Team. (2004). R: A language and environment for statistical computing. Vienna, Austria: R-Foundation for Statistical Computing. Retrieved June 18, 2008, from: http://www.R-project.org.

Roca, B., Gomez, C. J., & Arnedo, A. (1999). Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy. The Journal of Infection, 39, 141–145. doi:10.1016/S0163-4453(99)90006-3.CrossRefPubMed

Sharpe, T. T., Lee, L. M., Nakashima, A. K., Elam-Evans, L. D., & Fleming, P. L. (2004). Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. Journal of Community Health, 29, 117–127. doi:10.1023/B:JOHE.0000016716.99847.9b.CrossRefPubMed

Simoni, J. M., Pantalone, D. W., Plummer, M. D., & Huang, B. (2007). A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychology, 26, 488–495. doi:10.1037/0278-6133.26.4.488.CrossRefPubMed

Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R. D., & Altice, F. L. (2006). Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected DU. Journal of Acquired Immune Deficiency Syndromes, 43, S48–S53. doi:10.1097/01.qai.0000248338.74943.85.CrossRefPubMed

Strathdee, S. A., Palepu, A., Cornelisse, P. G., Yip, B., O’Shaughnessy, M. V., Montaner, J. S., et al. (1998). Barriers to use of free antiretroviral therapy in injection drug users. JAMA : The Journal of the American Medical Association, 280, 547–549. doi:10.1001/jama.280.6.547.CrossRef

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., et al. (2000). Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA : The Journal of the American Medical Association, 283, 2008–2012. doi:10.1001/jama.283.15.2008.CrossRef

Turner, B. J., Laine, C., Cosler, L., & Hauck, W. W. (2003). Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected DU. Journal of General Internal Medicine, 18, 248–257. doi:10.1046/j.1525-1497.2003.20122.x.CrossRefPubMed

van Houwelingen, H. C., Arends, L. R., & Stijnen, T. H. (2002). Tutorial in biostatistics. Advanced methods in meta-analysis: Multivariate approach and meta-regression. Statistics in Medicine, 21, 589–624. doi:10.1002/sim.1040.CrossRefPubMed

Viechtbauer, W. (2007). MiMa: An S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models. http://www.wvbauer.com/downloads/mima.ssc. Retrieved 18 June 2008.

Vissoci Reiche, E. M., Bonametti, A. M., Morimoto, H. K., Morimoto, A. A., Wiechemann, S. L., Matsuo, T., et al. (2008). Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infectedc patients from a southern Brazilian population. International Journal of Molecular Medicine, 21, 387–395.PubMed

Vlahov, D., & Celentano, D. D. (2006). Access to highly active antiretroviral therapy for injection DU: Adherence, resistance, and death. Cadernos de Saude Publica, 22, 705–718.PubMed

Wainberg, M. A., & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA: The Journal of the American Medical Association, 279, 1977–1983.CrossRef

Waldrop-Valverde, D., Ownby, R. L., Wilkie, F. L., Mack, A., Kumar, M., & Metsch, L. (2006). Neurocognitive aspects of medication adherence in HIV-positive injecting DU. AIDS and Behavior, 10, 287–297. doi:10.1007/s10461-005-9062-6.CrossRefPubMed

Waldrop-Valverde, D., & Valverde, E. (2005). Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting DU. AIDS Patient Care and STDs, 19, 326–334. doi:10.1089/apc.2005.19.326.CrossRefPubMed

Wang, C., Vlahov, D., Galai, N., Bareta, J., Strathdee, S. A., Nelson, K. E., et al. (2004). Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy: Implications for when to initiate therapy. The Journal of Infectious Diseases, 190, 1046–1054. doi:10.1086/422848.CrossRefPubMed

Wensing, A. M., van de Vijver, D. A., Angarano, G., Asjö, B., Balotta, C., Boeri, E., et al. (2005). Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. The Journal of Infectious Diseases, 192, 958–966.CrossRefPubMed

WHO/UNAIDS. (2007). Report on the global AIDS epidemic. Genebra: UNAIDS and WHO, 2007.

Wood, E., Hogg, R. S., Lima, V. D., Kerr, T., Yip, B., Marshall, B. D., et al. (2008). Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA: The Journal of the American Medical Association, 300, 550–554. doi:10.1001/jama.300.5.550.CrossRef

Wood, E., Hogg, R. S., Yip, B., Harrigan, P. R., O’Shaughnessy, M. V., & Montaner, J. S. (2004a). The impact of adherence on CD4 cell count responses among HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 35, 261–268. doi:10.1097/00126334-200403010-00006.CrossRefPubMed

Wood, E., Montaner, J. S., Bangsberg, D. R., Tyndall, M. W., Strathdee, S. A., O’Shaughnessy, M. V., et al. (2003a). Expanding access to HIV antiretroviral therapy to marginalised populations in the developed world. AIDS (London, England), 17, 2419–2427. doi:10.1097/00002030-200311210-00003.

Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O’Shaughnessy, M. V., et al. (2003b). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection DU. Canadian Medical Association Journal, 169, 656–661.PubMed

Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O’Shaughnessy, M. V., et al. (2004b). Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antiviral Therapy, 9, 229–235.PubMed

Titel: Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis
verfasst von: Monica Malta
Monica M. F. Magnanini
Steffanie A. Strathdee
Francisco I. Bastos
Publikationsdatum: 01.08.2010
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 4/2010
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-008-9489-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

High HIV Prevalence, Suboptimal HIV Testing, and Low Knowledge of HIV-Positive Serostatus Among Injection Drug Users in St. Petersburg, Russia

Unprotected Sex of Homeless Women Living in Los Angeles County: An Investigation of the Multiple Levels of Risk

Neighborhood-Level Correlates of Consistent Condom Use among Men Who have Sex with Men: A Multi-Level Analysis

Estimating Alcohol Content of Traditional Brew in Western Kenya Using Culturally Relevant Methods: The Case for Cost Over Volume

Hazardous Drinking and HIV Sexual Risk Behaviors Among Injection Drug Users in Developing and Transitional Countries